Taylor SA, et al. - In the prospective Streamline C trial with 1,020 patients, researchers prospectively compared the diagnostic accuracy and effectiveness of whole-body MRI (WB-MRI)-based staging pathways vs standard pathways in colorectal cancer. Eligible participants with newly diagnosed colorectal cancer were 18 years of age or older. Data reported that the mean staging costs per-patient were £216 for WB-MRI and £285 for standard pathways. Findings revealed that WB-MRI staging pathways have similar accuracy to standard pathways and decrease the number of tests, staging time and cost required. No adverse image-related events have been reported. Pathway sensitivity was 67% for WB-MRI and 63% for standard pathways and agreement with the multidisciplinary team's final treatment decision was 96% for WB-MRI and 95% for the standard pathway.